Wegovy BMI requirements explained (NHS and private)

Ready to take the next step? See if you're eligible for expert-led weight loss support.

Check your eligibility

Curious about the Wegovy BMI requirements? Discover the BMI cutoff for access to Wegovy through the NHS or private care.



Curious about the Wegovy BMI requirements? Discover the BMI cutoff for access to Wegovy through the NHS or private care.

If you're thinking about starting weight loss treatment with Wegovy, one of the first things you'll need to check is whether you meet the BMI requirements.


Body mass index (BMI) is a simple calculation that uses your weight and height to estimate your body fat. It's far from perfect, but it's the most widely used tool for assessing eligibility for GLP-1 weight loss medication in both NHS and private care.

Here's what you need to know about Wegovy BMI requirements and how to get started safely.


NHS vs private: key differences in BMI cutoffs for treatment

Wegovy is available through both the NHS and private providers like SemaPen, but the BMI requirements aren't the same. Here's a quick breakdown.


BMI requirement Weight-related health condition is required Access pathway
NHS At least 35 (or 30–34.9 plus extra criteria) Yes GP first, then referral to a specialist
Private (e.g. SemaPen) At least 30 (or 27–29.9 with related health condition) Yes (if BMI 27-29.9) Private medical assessment

NHS access to Wegovy: stricter criteria and a slower process

Wegovy became available through the NHS UK for weight loss in September 2023, but GPs don't prescribe it directly. People must be referred to specialist weight management services to access Wegovy.

To qualify, patients generally need:

  • A BMI of 35 or more
  • A weight-related health condition, such as type 2 diabetes, high cholesterol or sleep apnoea
  • Documented attempts to lose weight through lifestyle changes
  • To be willing to follow a multidisciplinary weight-loss plan that includes diet and exercise

In some cases, people with a BMI between 30 and 34.9 may qualify if they have a significant obesity-related condition. A person's ethnic background may also be taken into account, since people from certain groups may experience health risks at a lower BMI.


The NHS criteria are designed to ensure that those at most risk receive support. But the process can be lengthy, and many people face long wait times for assessment and treatment.


Picture of hospital waiting room.

For full details, please see the official NHS guidance.

Private access: broader criteria and faster access to care

Private providers can prescribe Wegovy to a wider group of people. While the same medication is used, the process is more flexible and designed around your individual health status, not your local referral system.

You may be eligible for Wegovy privately if:

  • Your BMI is 30 or higher
  • Your BMI is between 27 and 29.9, and you have a related condition such as prediabetes, insulin resistance, high blood pressure or high cholesterol

As with the NHS criteria, a person's ethnic background is also considered.

At SemaPen, every patient completes a secure online health assessment reviewed by a licensed UK prescriber. If your BMI is in the lower range, your medical history will be evaluated to make sure semaglutide is safe and appropriate for you. This includes checking for medications that might interact and any conditions that could affect treatment.

There's no need for a GP referral. Instead, access is based on your needs and your eligibility.

SemaPen: your path to safe, supported weight loss

Do you meet the BMI criteria and want to explore semaglutide safely and effectively? Our team of obesity specialists is here to help. SemaPen's expert-led medical weight loss plans combine prescription access with remote monitoring, smart scales and compassionate support.

We make it easy to:

  • Check your eligibility quickly online
  • Get reviewed by a licensed UK prescriber
  • Access the right GLP-1 medication for you, whether that's Wegovy (semaglutide) or Mounjaro (tirzepatide)
  • Stay supported with regular check-ins and smart tracking

Are you ready to take the next step on your weight loss journey, with expert support focused on your goals? You can get started today by taking our online health assessment. Our specialists will review your answers and recommend a tailored treatment for you.

Sources

1. DHSC Media Team (2024) Accessing Wegovy for weight loss: Everything you need to know. GOV.UK. Retrieved from https://healthmedia.blog.gov.uk/2023/09/04/accessing-wegovy-for-weight-loss-everything-you-need-to-know/

This article was reviewed and approved by Alice Fletcher, Lead Bariatric Dietitian, on 31 July 2025.


  • Average 15-21% weight loss*
  • Tailored programmes built by real experts
  • Targeted support to make success feel simpler
  • Unique app with weight loss tools and lessons

Your journey starts here

Start your personalised weight loss plan in minutes.

1

Start your online consultation

2

Get approved by our clinical team

3

Begin your programme

Get started
Get the key facts about carbohydrates. Learn about their role in weight management
by Simon Edward 10 April 2026
Get the key facts about carbohydrates. Learn about their role in weight management and where they fit into a balanced diet.
Just starting out on your journey to sustainable health? Explore simple, evidence-based weight loss
by Simon Edward 6 April 2026
Just starting out on your journey to sustainable health? Explore simple, evidence-based weight loss tips for beginners.
Taking Mounjaro weight loss injections might affect how warfarin tablets are absorbed into the body.
by Simon Edward 31 March 2026
Taking Mounjaro weight loss injections might affect how warfarin tablets are absorbed into the body. Learn what this means for you as a patient.
Compounded semaglutide is an unlicensed version of the active ingredient found in Wegovy.
by Simon Edward 31 March 2026
Compounded semaglutide is an unlicensed version of the active ingredient found in Wegovy. Get all the straight facts in our quick guide.
A new tablet-based medication has beaten oral semaglutide (Rybelsus) for weight loss.
by Simon Edward 30 March 2026
A new tablet-based medication has beaten oral semaglutide (Rybelsus) for weight loss. Let's unpack the results to see what they really mean.
Is there a secret to maximising weight loss on Mounjaro? Follow our step-by-step guide
by Simon Edward 27 March 2026
Is there a secret to maximising weight loss on Mounjaro? Follow our step-by-step guide for straight facts and evidence-based tips.
Are you planning to take your Wegovy or Mounjaro weight loss pens abroad? Here are all the key facts
by Simon Edward 23 March 2026
Are you planning to take your Wegovy or Mounjaro weight loss pens abroad? Here are all the key facts you need to know.
There are many causes of obesity, but can genetics play a part? Learn how
by Simon Edward 20 March 2026
There are many causes of obesity, but can genetics play a part? Learn how our DNA can influence our weight, and what we can do about it.
Learn about the link between obesity and kidney stones, and whether weight loss medication can help
by Simon Edward 16 March 2026
Learn about the link between obesity and kidney stones, and whether weight loss medication can help to reduce risk.
Want to improve your diet? Learn what protein is, how much you need
by Simon Edward 13 March 2026
Want to improve your diet? Learn what protein is, how much you need and how good nutrition supports healthy weight loss.
More posts